Consumer News Eli Lilly Says Its New Diabetes Drug Was 94 Effective In Clinical Trials

Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials

Eli Lilly and Company (LLY) on Wednesday said that its oral GLP-1 drug Orforglipron lowered blood glucose levels in two late-stage trials, confirming its potential in treating type-2 diabetes. While ... Read More

Eli Lilly's Weight-Loss Drug Meets Primary Endpoint in Diabetes Trials

Eli Lilly said its investigational oral GLP-1 weight-loss drug, orforglipron, met its primary endpoints in two recent phase 3 trials. The medicine company said Wednesday the drug met the primary and ... Read More

Eli Lilly oral weight loss drug succeeds in late-stage trials for diabetes

Eli Lilly (NYSE:LLY) announced on Wednesday that its oral weight loss candidate, orforglipron, reached the main goals in two Phase 3 trials for patients with type 2 diabetes, indicating its potential ... Read More

Eli Lilly's orforglipron bests Farxiga, padding oral GLP-1 case with pair of phase 3 diabetes wins

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ... Read More

Lilly's weight-loss pill shows better blood sugar control in late-stage trials

Oct 15 (Reuters) - Eli Lilly's (LLY.N), opens new tab experimental weight-loss pill showed superior blood sugar control in diabetic patients across two late-stage trials, the company said on Wednesday ... Read More

Sanofi, Lilly among winners of EU drug recommendations this week

During a meeting this week, an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed 10 new medicines for approval, including a diabetes drug from Sanofi (SNY) and a ... Read More

Novo, Eli Lilly oral obesity drugs included in new FDA priority voucher program

Experimental pill versions of GLP-1 weight loss drugs by Novo Nordisk and Eli Lilly will receive FDA priority review. Read more here. Read More

Trump rolls out pricing deal with weight-loss-drug giants Eli Lilly, Novo Nordisk. Analysts say the pact raises more questions than it answers.

The Trump administration on Thursday rolled out a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicare ... Read More